Studies focusing on arterial thrombosis with SGLT2 inhibitors have been limited, but in another meta‐analysis by Lin et al.32that assessed lower limb complications, the risk of peripheral arterial disease events, which comprised arterial thrombosis, was significantly elevated with SGLT2 inhibitor use. This evidence concerns the gene SLC5A2 and peripheral arterial disease.